FDA Grants Immunotherapy Duo a Priority Review for Kidney Cancer – Curetoday.com
OncLive |
FDA Grants Immunotherapy Duo a Priority Review for Kidney Cancer
Curetoday.com Adverse events (AEs) leading to discontinuation occurred in 22 percent of patients in the combination immunotherapy group compared with 12 percent in the Sutent group. The most common grade 3/4 AEs in the combination group were fatigue (4 percent) and … Immuno-Oncology Market Demand to Exceed US$ 27846.3 Mn During 2017 – 2025 FDA Grants Nivolumab/Ipilimumab Priority Review for RCC |
